ALT Stock Summary and Trading Ideas (Altimmune | NASDAQ:ALT)

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

Altimmune trades on the NASDAQ stock market under the symbol ALT.

As of April 19, 2024, ALT stock price climbed to $6.91 with 3,496,555 million shares trading.

ALT has a beta of 2.56, meaning it tends to be more sensitive to market movements. ALT has a correlation of 0.08 to the broad based SPY ETF.

ALT has a market cap of $371.27 million. This is considered a Small Cap stock.

In the last 3 years, ALT stock traded as high as $23.49 and as low as $2.09.

The top ETF exchange traded funds that ALT belongs to (by Net Assets): XBI, VTI, IWM, VXF, LABU.

ALT has underperformed the market in the last year with a price return of +15.7% while the SPY ETF gained +21.2%. ALT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.3% and -24.0%, respectively, while the SPY returned +3.0% and -4.5%, respectively.

ALT support price is $6.47 and resistance is $7.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALT stock will trade within this expected range on the day.